1. BioClonetics Patents, Publications and Prior Grants
2. BioClonetics European Patent
3. Company Publications
4. Prior Grants

BioClonetics U.S. Pending and Issued Patents and Trade Secret Technologies:

View Larger

BioClonetics Patent Application for “Anti-HIV Small Molecular Peptides”, Serial No. 61295979, filed January 18, 2010. BioClonetics Patent Application for “Anti-HIV Small Molecular Peptides”, Serial No. 61296110, filed January 19, 2010. For HIV to infect the targeted human CD4+ cell, the virus must bind to 1st and 2nd co receptors to gain entry into the CD4+ cell and complete the cycle of infection. The BioClonetics recent applications cover the improved and commercially optimum use of small molecules for interrupting and preventing the binding between the virus and the CD4+ cell at the 2nd co-receptor. When binding is prevented, the virus is neutralized. Proprietary trade-secret methodologies and processes for creating immortalized cells that stably produce human monoclonal antibodies. U.S. Patent No. 5,459,060, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued October 17, 1995. View Patent U.S. Patent No. 5,777,074, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued July 7, 1998. View Patent U.S. Patent No. 6,008,044, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV) and Detection of Antibodies Against Epitope (GCSGKLIC), issued Dec. 18, 1999. View Patent U.S. Patent No. 6,083,504, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued July 4, 2000. View Patent

These four U.S. Patents cover (1) the  human  monoclonal antibodies of CLONE 3 which have been demonstrated to neutralize both laboratory and geographically diverse clinical HIV isolates, (2) a vaccine, identified by monoclonal antibody binding, analogous to the neutralizable fusion-associated epitope amino acid peptide sequence [GCSGKLIC] which will elicit protective antibodies against HIV, and (3) all synthetic inhibitory peptides (mini-antibodies) which bind to the fusion-associated sequence of the virus (anti-viral therapy).

European Patent (EPC) No. 0492560, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1, issued October 10, 2001.   This EPC patent is a corresponding counterpart to the Company’s U.S. patents.
View Patent

• Cotropia, J.P., Ugen, K.E., Lambert, D., Ljunggren-Broliden, K., Kliks, S., Hoxie, J., and Weiner, D.B., Characterization of Human Monoclonal Antibodies to the HIV-1 Transmembrane gp41 Protein.  In Vaccines 92:  Modern Approaches to New Vaccines Including Prevention of AIDS. (ed. F. Brown et al.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York  1992.
• Kliks, S., Cotropia, J.P., Weiss, C., Katinger, H., and Levy, J.A., Synergism of Broadly Neutralizing Effect by Two Transmembrane Envelope gp41 Monoclonal Antibodies [Clone 3 Antibody + 2F5].  Conference on Advances in AIDS Vaccine Development, Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (Reston, VA) November 6 - 10, 1994.
• Ugen, K., Srikantan, V., Wang, B., Goedert, H., Ziegner, U., Agadjanyan, M.G., Boyer, J.D., Cotropia, J.P., Williams, W.V.,  and Weiner, D.B., Vertical Transmission of Human Retroviral Infections:  Immunological Parameters.  Archives of STD/HIV Research, 8:283-292, 1994.
• Cotropia, J.P., Ugen, K.E., Kliks, S., Broliden, K., Broliden, P-A., Hoxie, J.A., Srikatan, V., Williams, W.V., Weiner, D.B., A Human Monoclonal Antibody to HIV-1 gp41 with Neutralizing Activity Against Diverse Laboratory Isolates.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12(3):221-232, 1996.
• Cotropia, J.P., Ugen, K.E., "Passive Immunotherapy Against HIV-1: Current Status and Future Potential" in Human Retroviral Infections : Immunological and Therapeutic Control, edited by Kenneth E. Ugen, Herman Friedman and Mauro Bendinelli (Volume of the Series : Infectious Agents and Pathogenesis. Series Editors : Mauro Bendinelli and Herman Friedman), Plenum Press , New York and London, 2000.
• Viveros, M., Dickey, C., Cotropia, J.P., Gevorkian, G., Larralde, C., Broliden, K., Levi, M., Burgess, A., Weiner, D.B., Agadjanyan, M., and Ugen, K.E., Characterization of a Novel Human Immunodeficiency Virus Type 1 Neutralizable Epitope within the Immunodominant Region of gp41, Virology, 270:135-145, 2000.
• Cotropia, J.P., and Ugen, K.E., Passive Immunotherapy against HIV-1:  Current Status and Potential, in Human Retroviral Infections—Immunological and Therapeutic Control, (eds. Ugen, K.E., Bendinelli, M., and Friedman, H.), Kluwer Academic/Plenum Publishers (New York) 217-238, 2000.
• lavia Ferrantelli, Moiz Kitabwalla, Robert A. Rasmussen, Chuanhai Cao, Ting-Chao Chou, Hermann Katinger, Gabriela Stiegler, Lasa M. Cavacini, Yun Bai, Joseph Cotropia, Kenneth E. Ugen, and Ruth M. Rupprecht. Potent Cross-Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodies--Implications for Acquired Immunodeficiency Syndrome Vaccine. Journal of Infectious Diseases 189, (1):71-74, 2004.
• Chuanhai Cao, Yun Bai, Mary Jolene Holloway, Joseph Cotropia, and Kenneth E. Ugen.  Characterization of a Novel Human Anti-HIV1 gp41 IgM Monoclonal Antibody Designated as Clone 37, DNA and Cell Biology 23 (12), 40-45, 2004.
• Chuanhai Cao, Gabriela Stiegler, Andrew W.E. Burgess, Yun Bai, Hermann Katinger, Joseph P. Cotropia, Hiuqin Dong, Rebecca L. Edgeworth, Eugene A. Jackson, Flavia Ferrantelli, Ruth M. Ruprecht, and Kenneth E. Ugen. Cross-Clade Neutralization of Clinical HIV Isolates by a Novel Anti-gp41 Human Monoclonal Antibody, January 2007 submitted.